SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-21-040205
Filing Date
2021-12-03
Accepted
2021-12-03 12:00:19
Documents
14
Period of Report
2021-12-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10031464_8k.htm   iXBRL 8-K 30970
2 EXHIBIT 99.1 brhc10031464_ex99-1.htm EX-99.1 25000
6 image00001.jpg GRAPHIC 5319
  Complete submission text file 0001140361-21-040205.txt   211146

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20211203.xsd EX-101.SCH 3959
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20211203_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20211203_pre.xml EX-101.PRE 16066
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10031464_8k_htm.xml XML 4244
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 211469206
SIC: 2834 Pharmaceutical Preparations